CARMIL1

Across TCGA pan-cancer cohorts, CARMIL1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CARMIL1 data layer compared with 22 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CARMIL1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CARMIL1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, COAD, and LSCC are the cancer types where CARMIL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.416	0.184	.004	32	view →
COAD	DFS	Tertile	All	1.000	0.884	.039	24	view →
LSCC	DFS	Quartile	All	0.932	0.609	.002	6	view →
CCRCC	OS	Quartile	III,IV	1.000	0.697	.025	4	view →
LUAD	DFS	Tertile	III,IV	0.249	0.706	.034	3	view →
GBM	OS	Median	All	0.954	0.760	.005	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CARMIL1–PDAC (DFS)

Open the PDAC breakdown →